Effects of Oxygen on the human body

Effects of Hyperoxia on Haemostasis, Inflammation and oxidative Stress

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-003962-10-AT

Enrollment

Registered

2015-10-30

Start date

2015-12-10

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effects of hyperoxia on haemostasis, inflammation and reactive oxygen species

Interventions

Trade Name: Oxygen MedicAL 100% (V/V) Product Name: Oxygen MedicAL 100% (V/V) Product Code: 6948638.00.00 Pharmaceutical Form: Medicinal gas, compressed INN or Proposed INN: OXYGEN CAS Number: 7782-44

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: healthy male participants Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: age under 18, over 65 years BMI >25kg/m2 Female Smoker, Diver Medication, Diseases

Design outcomes

Primary

Measure	Time frame
Main Objective: Hyperoxia induces ROS in leucocytes;Secondary Objective: Hyperoxia induces inflammation and interacts with the blood coagulation;Primary end point(s): Effects of hyperoxia on ROS;Timepoint(s) of evaluation of this end point: t0 before intervention t1 after intervention t2 one hour after intervention t3 two hours after intervention t4 four hours after intervention t5 24 hours after intervention	—

Measure

Time frame

Main Objective: Hyperoxia induces ROS in leucocytes;Secondary Objective: Hyperoxia induces inflammation and interacts with the blood coagulation;Primary end point(s): Effects of hyperoxia on ROS;Timepoint(s) of evaluation of this end point: t0 before intervention t1 after intervention t2 one hour after intervention t3 two hours after intervention t4 four hours after intervention t5 24 hours after intervention

—

Secondary

Measure	Time frame
Secondary end point(s): Effects of Hyperoxia on haemostasis and inflammation;Timepoint(s) of evaluation of this end point: t0 before intervention t1 after intervention t2 one hour after intervention t3 two hours after intervention t4 four hours after intervention t5 24 hours after intervention	—

Countries

Austria

Contacts

Public ContactDepartment of Anaesthesia

Medical University of Vienna

gisela.scharbert@meduniwien.ac.at004314040041440

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026